Head-to-head · Cost-Efficiency Index
CoreAge Rx vs Hers
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
CoreAge Rx
Anyone optimizing for real value — a transparent flat price you can model for a full year, nationwide, without a bait-and-switch.
Visit CoreAge RxHers
Cost-first shoppers who want brand-name FDA-approved GLP-1 access with a mainstream telehealth name.
Visit HersThe verdict
CoreAge Rx takes it, leading the Cost-Efficiency Index 94 to 58. Best value in the ranking: both molecules at one flat, all-50 price with no teaser step-ups — the lowest true cost of ownership, not the lowest teaser. Hers still earns a C — Cost-first shoppers who want brand-name FDA-approved GLP-1 access with a mainstream telehealth name.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | CoreAge Rx | Hers |
|---|---|---|
| Cost-Efficiency Index | 94/100 | 58/100 |
| Semaglutide / mo | $99/mo | $348/mo (brand Wegovy, plus a separate fee) |
| Tirzepatide / mo | $149/mo | $448/mo (brand Zepbound, plus a separate fee) |
| Semaglutide / yr (modeled) | $1,188 | $4,176 |
| Tirzepatide / yr (modeled) | $1,788 | $5,376 |
| Coverage | All 50 states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #1 | #279 |
CoreAge Rx
94/100Where the value is
- Flat all-in monthly price — no intro rate that silently triples after month one, so the modeled annual cost is the real cost
- Both compounded semaglutide and tirzepatide on one account at published prices
- Available in all 50 states — no coverage gamble
The tradeoffs
- Not the rock-bottom sticker price — 30 of the 381 priced semaglutide programs we track list a cheaper figure, though most attach a term or a step-up that CoreAge does not
- No FDA-approved brand-name option (compounded only)
Hers
58/100Where the value is
- Sells only FDA-approved branded medications (Wegovy, Zepbound, Ozempic, Mounjaro) rather than compounded versions
- Multiple formats per drug (pill vs pen/vial), including a newer pill option and microdosing plan
- Large, publicly traded parent (Hims & Hers Health) with an established clinical/support infrastructure
The tradeoffs
- The advertised 'From $X/mo' price is medication-only — a mandatory membership fee ($39 first month, then $149/mo, billed separately) is layered on top and roughly doubles the real steady-state monthly cost
- No compounded, lower-cost semaglutide/tirzepatide option was found on the current site
Regulatory note: the FDA issued a warning letter to Hims & Hers Health, Inc. dba Hers in September 2025. We still list and link to Hers; you should know the letter is on the public record before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.